China Merchants Securities appeared to be the Corporate Investor, which was created in 1991. The company was established in Asia in China. The leading representative office of defined Corporate Investor is situated in the Shenzhen.
We also calculated 10 valuable employees in our database.
The fund has no specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, E-Commerce. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight SenseTime, GRAIL, Kingsoft Cloud.
The typical case for the fund is to invest in rounds with 7 participants. Despite the China Merchants Securities, startups are often financed by IDG Capital, BlueRun Ventures, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are CICC, Zhongping Capital, ZJ Innopark (Zhangjiang Hi-Tech Park). In the next rounds fund is usually obtained by Kingsoft, Tiger Global Management, Temasek Holdings.
The typical startup value when the investment from China Merchants Securities is 500 millions - 1 billion dollars. The usual things for fund are deals in the range of more than 100 millions dollars. The important activity for fund was in 2016. The fund is generally included in less than 2 deals every year. The real fund results show that this Corporate Investor is 20 percentage points more often commits exit comparing to other companies.
Related Funds
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Aixin Semiconductor Technology | 25 Jan 2024 | Guangdong, Tianjin, China | |||
Wei Gao Jie Kang Biological Material | 24 Aug 2023 | China, China | |||
Porton Advanced Solutions | $80M | 21 Aug 2022 | Suzhou, Jiangsu, China | ||
Proton Bio | $80M | 19 Aug 2022 | Suzhou, Jiangsu, China | ||
Aoquan | $15M | 05 Aug 2022 | Shanghai, Shanghai, China | ||
Data Grand | $89M | 09 Mar 2022 | Shanghai, China | ||
Regend Therapeutics | $15M | 03 Mar 2022 | Suzhou, Jiangsu, China | ||
Sheng Microelectronics | $15M | 18 Feb 2022 | Suzhou, Jiangsu, China | ||
Jifan Biotechnology | $15M | 13 Dec 2021 | Changping, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Aixin Semiconductor Technology | 25 Jan 2024 | Guangdong, Tianjin, China | |||
Wei Gao Jie Kang Biological Material | 24 Aug 2023 | China, China | |||
Porton Advanced Solutions | $80M | 21 Aug 2022 | Suzhou, Jiangsu, China | ||
Proton Bio | $80M | 19 Aug 2022 | Suzhou, Jiangsu, China | ||
Aoquan | $15M | 05 Aug 2022 | Shanghai, Shanghai, China | ||
Data Grand | $89M | 09 Mar 2022 | Shanghai, China | ||
Regend Therapeutics | $15M | 03 Mar 2022 | Suzhou, Jiangsu, China | ||
Sheng Microelectronics | $15M | 18 Feb 2022 | Suzhou, Jiangsu, China | ||
Jifan Biotechnology | $15M | 13 Dec 2021 | Changping, Beijing, China |